In a new study published October 24 in the journal Cell, a scientific team has shown that bioinformatically optimized HIV vaccine antigens known as “mosaic” antigens might be useful in the design of a global HIV vaccine.
Researchers from around the world will gather at the annual AIDS Vaccine conference October 7-10 in Barcelona. See the research MHRP and RV144 collaborators will present.
The program aims to increase the availability, quality and utilization of gender based violence (GBV) services as well as to reduce the societal acceptance of GBV.
MHRP researcher and liposome pioneer Dr. Carl Alving and his team deconstruct the underlying science behind the physical structure of the world’s most potent vaccine adjuvant.
